Darren Scoggin
Jackson, MSNPI 1558772558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 209 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$667
- Corium, LLC$427
- GSK$359
- Tris Pharma Inc$327
- Pfizer$325
- Merck$234
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,379100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 46 | $667 |
| Corium, LLC | 24 | $427 |
| GSK | 26 | $359 |
| Tris Pharma Inc | 19 | $327 |
| Pfizer | 21 | $325 |
| Merck | 15 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $230 |
| Sanofi Pasteur Inc. | 10 | $218 |
| Collegium Pharmaceutical, Inc. | 11 | $148 |
| Supernus Pharmaceuticals, Inc. | 4 | $123 |
| AstraZeneca | 3 | $49 |
| Vertical Pharmaceuticals, LLC | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Kaleo, Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Genentech USA, Inc. | 2 | $25 |
| Abbott | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Biomarin Pharmaceutical Inc. | 1 | $14 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.